AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$CHE

What Chemed (CHE) Said on Its Q3 Earnings Call

Chemed reported Q3 earnings, with Roto-Rooter revenue up 7.5% but EBITDA down 2.5% due to higher costs. Commercial revenue grew 9% to $59.9M, while residential rose 5.2% to $158.8M. The company acquired California franchises for $62.5M, expecting $30M-$35M in 2027 revenue but less than $4M in EBITDA. Chemed repurchased 125,000 shares for $66M. Management expects 2026 EPS to meet or slightly exceed guidance.

Original reporting
finance.yahoo.com
Published Oct 29, 2026, 7:04 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 7:13 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
What Chemed (CHE) Said on Its Q3 Earnings Call — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$CHEBullishMed
01

Why it matters

Earnings guidance near high end, $66M share repurchase, and a $62.5M franchise acquisition provide mixed signals for investors.

02

Market read

Earnings and strategic moves may cause modest price movement; investors should watch integration progress.

03

What to watch

Potential for improved margins once franchise integration completes in 12-18 months.

Relevance 7/10Novelty 6/10Timing: post-market after earnings call

Background

Chemed Corp (NYSE:CHE) operates VITAS Healthcare and Roto-Rooter, reporting Q3 results and strategic actions.

Company-level read

Ticker impact

$CHEBullishMedium confidence
Context

Q3 earnings call disclosed adjusted EPS guidance near high end, $66M share repurchase and $62.5M franchise acquisition details.

Expected impact

likely modest downside as market prices in lower margin acquisition and fuel cost headwinds

Evidence & confidence

Share repurchase shows confidence, but acquisition costs and lower EBITDA margins may weigh on earnings outlook.

Market effects

Sector

Roto-Rooter acquisition highlights consolidation in residential services, may pressure peers' margins.

Regional

U.S. residential service sector sees mixed signals from Chemed's earnings.

Global

Limited to U.S. market; no broader macro impact.

Counterpoint

What could challenge this read

Buyback could outweigh acquisition costs, presenting a short-term upside opportunity.

Key entities

  • Company
    Chemed Corp

    Provider of healthcare and residential/commercial services.

Read at source← All news

StoryChemed reports Q3 2026 earnings with double‑digit revenue growth and $62.5 M California franchise acquisition

Also covered by

4 outlets

Related articles

$CHEMedAI 9/10

Chemed 3Q 2026: Revenue $690.9M, EPS $5.45— 10-Q Summary

Chemed reported Q3 2026 revenue of $690.9M, up 10.6% YoY, with net income rising 11.5% to $71.6M and EPS increasing 22.2% to $5.45. Growth in VITAS and Roto-Rooter segments drove results, while higher fuel costs pressured margins. The company acquired RotoCo and other franchises, expanding its territories.

tradingview.com
$CHEMed

Chemed outlines 12- to 18-month integration timeline for $62.5M California Roto-Rooter franchise buyback while expecting 2026 EPS at or slightly above prior high end (NYSE:CHE)

Chemed (CHE) announced a 12- to 18-month integration timeline for its $62.5M California Roto-Rooter franchise buyback. CEO Kevin McNamara reported VITAS revenue grew 12.2% year-over-year, driven by ADC growth and cost containment. The company expects 2026 EPS to be at or slightly above the prior high end.

seekingalpha.com
$CHEHighAI 8/10

Chemed (CHE) Q3 2026 Earnings Call Transcript

Chemed (CHE) reported Q3 2026 earnings with total revenue up 10.6% and adjusted EPS up 28.1% YoY. VITAS saw 12.2% revenue growth, while Roto Rooter grew 7.5%. Roto Rooter's margins declined due to higher marketing costs and fuel expenses, but acquisitions are expected to drive long-term growth. The company has $229M in cash flow from operations, enabling strategic acquisitions and share repurchases.

finance.yahoo.com
$CHEHighAI 8/10

Why is Chemed stock surging today?

Chemed (CHE) stock rose 9.2% after Q3 earnings beat estimates, with adjusted EPS of $6.75 and revenue of $690.9M. VITAS hospice division showed strong growth. Jefferies upgraded the stock to Buy, raising its price target to $620. Bank of America also increased its target to $555. The stock hit a 52-week high.

investing.com